Bringing Your Medical Device Innovations To Market
From feasibility to full-scale manufacturing. Specialist electrospinning for medical devices.
Manufacturability by design
Every programme follows an established process and builds on years of experience, giving your device the strongest possible foundation for manufacturing.Â
ISO 13485 certified since 2015
100+ feasibility projects
5 FDA 510(k)-cleared devices
ISO Class 7 cleanroom manufacturing
10+ years in medical device electrospinning
Global clients From across US, EU, Israel and UK
Electrospinning for medical devices.
The Electrospinning Company has built everything around its core capability: four proprietary technology platforms, ISO 13485-certified processes, cleanroom manufacturing infrastructure, and a development methodology shaped by more than a decade of medical device programmes.
That focus means the team comes to every programme already fluent in the manufacturing, regulatory and scale-up challenges that electrospun components carry, so your team can move straight into the work that matters.
The Electrospinning Company works as an extension of your team, integrating with your existing architecture, suppliers and design controls. The team is straightforward to work with - clear communication, responsive turnaround, and a collaborative approach from feasibility through to manufacturing.

Cardiovascular Applications
Coatings, coverings and scaffold structures for stents, heart valves, vascular grafts and occlusion devices. Engineered for improved adhesion and long-term implant performance.
Four proprietary platforms. One development partner.
Caladrix®
Advanced device coverings with superior adhesion for stents, valves, and occlusion devices
Symatix®
Biosynthetic materials combining natural compounds with synthetic fibres for enhanced biocompatibility
Kalyptix®
Permanent, non-woven materials designed for long-term implantation with optimal tissue integration
Delivering Measurable Results For Medical Innovation
See how our materials enhance device performance and patient outcomes

